Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site
The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogene autotemcel) developed and launched by Vertex Pharmaceuticals.
Biomay's recent achievement refers to an inspection by the FDA's Center for Biologics Evaluation and Research (CBER) at Biomay's headquarters manufacturing site in Vienna, Seestadt in December 2024. No observation was found, and no Form FDA 483 was issued by the authority, allowing Biomay's headquarters site to supply Cas9 for the United States.
Biomay operates two independent cGMP manufacturing sites, a headquarters facility in Vienna Seestadt, and a second site in Vienna downtown. The authority’s approval of Biomay's headquarters site represents the company's second successful FDA inspection following the 2023 approval of Biomay's downtown facility. Biomay's headquarters site is a recently constructed, state-of-the-art biomanufacturing facility.
Biomay AG is a privately owned and fully integrated Contract Development and Manufacturing Organization (CDMO) based in Vienna, Austria. Founded in 1984, the expression of recombinant proteins by utilizing E. coli has been Biomay's business focus from the very beginning. Today, Biomay offers cGMP services for manufacturing of therapeutic proteins, plasmid DNA (pDNA) and messenger RNA (mRNA). The company's scope of CDMO services comprises process and analytical development, cell banking, cGMP manufacturing of drug substance and aseptic filling of drug product.
Contact:
Dr. Angela Neubauer, SVP Client Business; E-Mail: request@biomay.com / Biomay AG, Ada Lovelace-Str. 2, A-1220 Vienna, Austria www.biomay.com
Images
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Nominations for the Broermann Medical Innovation Award 2026 now open5.9.2025 09:13:31 CEST | Press release
With a million euros, it is one of the world’s most highly endowed awards for medical research
Europe’s Digital Paradox: Citizens Feel Abandoned by Companies and Authorities on Cybersecurity - yet They also Don’t Protect Themselves4.9.2025 10:00:00 CEST | Press release
A representative study of 14,000 Europeans highlights citizens’ concerns about digital threats and data sovereignty. Major concerns include identity theft, financial uncertainty and the effects of cyberattacks on democracy. While citizens recognize cybersecurity deficiencies and have little trust in companies and authorities, they do not take personal responsibility for their own protection.
Grünenthal PRO is joining SHL Medical’s alliance partnership network to offer final assembly service for Molly® autoinjectors4.9.2025 10:00:00 CEST | Press release
Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery systems. Through this collaboration, Grünenthal PRO will offer final assembly, packaging and labelling of Molly® autoinjector. Grünenthal PRO will expand its capacity for final assembly of SHL autoinjectors by installing additional assembly lines in its Origgio, Italy facility in 2026. These new pre-validated lines for Molly® 1.0 and 2.25 mL autoinjector platform will enhance speed-to-market for pharma and biotech companies, building on Grünenthal’s 10 year-experience in SHL autoinjector assembly services. In parallel, SHL customers will benefit from access to Grünenthal PRO’s established expertise and capacity in delivering high quality, reliable contract manufacturing services. “Speed-to-mar
From Grid Load to Revenue Stream: PLAN-B NET ZERO Makes the Energy Transition Economically Successful3.9.2025 11:44:39 CEST | Press release
Berlin, Berlin-based GreenTech startup PLAN-B NET ZERO BESS GmbH, a subsidiary of PLAN-B NET ZERO AG specialising in innovative energy storage solutions, demonstrates how its battery energy storage systems (BESS) enable businesses and private households to profit directly from the growing imbalance between very low and very high prices on the electricity exchange (EEX).
Seeding The Future Foundation, Institute of Food Technologists, and Welthungerhilfe Announce Evolution of the Seeding The Future Global Food System Challenge2.9.2025 14:12:44 CEST | Press release
(Plymouth, Minnesota; Chicago, Illinois; Bonn, Germany) — The Seeding The Future Foundation (STF), the Institute of Food Technologists (IFT), and Welthungerhilfe (WHH) today announced the next chapter of the Seeding The Future Global Food System Challenge (GFSC). With the conclusion of its fourth cycle, operations will transition from IFT to WHH, an international leader in food systems transformation and the fight against hunger in the Global South. Launched by STF in 2021 and hosted by IFT, the Challenge has become a premier platform for advancing breakthrough innovations. Over four years, it has drawn more than 4,000 applications from 97 countries, awarding $1 million annually to visionary teams tackling urgent food system challenges. The program has accelerated solutions that improve food security, reduce environmental impact, and build resilience in vulnerable communities. “We are incredibly proud of what the Challenge has achieved and the vital role we played in helping visionary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom